Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug2892 | Ruxolitinib Wiki | 0.32 |
drug2557 | Placebo oral tablet Wiki | 0.17 |
Navigate: Correlations HPO
There is one clinical trial.
The purpose of this study is to evaluate the efficacy and safety of metformin glycinate at dose of 620 mg twice per day plus standard treatment comparing to standard treatment alone (we will use placebo) of patients who have metabolic syndrome or type 2 diabetes, which have severe acute respiratory syndrome secondary to SARS-CoV-2.
Description: Assess differences in SARS-CoV-2 viral load between participants that receive placebo vs metformin glycinate
Measure: Viral Load Time: Day 0 to Day 8 or patient discharge dayDescription: Assess length of supplementary oxygen
Measure: Days of supplementary oxygen if apply Time: Day 0 to day 28 or patient discharge dayDescription: Assess length of mechanical ventilation
Measure: Days of supplementary mechanical ventilation if apply Time: Day 0 to day 28 or patient discharge dayDescription: Assess length of hospitalization
Measure: Days of Hospitalization Time: Day 0 to day 28 or patients discharge dayDescription: Assess the difference in the Proportion of participants with normalization of fever between participants that receive placebo vs the patients with metformin glycinate
Measure: Normalization of fever Time: Day 0 to day 28 or patient discharge dayDescription: Assess the difference in the Proportion of participants with normalization of oxygen saturation between participants that receive placebo vs the patients with metformin glycinate
Measure: Normalization of oxigen saturation Time: Day 0 to day 28 or patient discharge dayDescription: Assess the difference in the number of deaths between participants who received placebo versus the patients with metformin glycinate
Measure: Number of deaths Time: Day 0 to day 28 or patient discharge dayDescription: Evaluate if the level increase or decrease in serum creatinine compared to baseline. units: mg/dl
Measure: Change in Serum creatinine levels Time: Day 0 to day 28 or patients discharge dayDescription: Evaluate if the level increase or decrease in serum Creatine kinase-MB compared to baseline. Units: UI/l
Measure: Change in serum Troponin I Time: Day 0 to day 28 or patients discharge dayDescription: Evaluate if the level increase or decrease in serum aspartate aminotransferase compared to baseline. units: IU/l
Measure: Change in serum aspartate aminotransferase levels Time: Day 0 to day 28 or patients discharge dayDescription: Evaluate if the level increase or decrease in serum Creatine kinase-MB compared to baseline. Units: UI/l
Measure: Change in serum Creatine kinase-MB levels Time: Day 0 to day 28 or patients discharge dayDescription: Assess by incidence of grade 3, grade 4 and Serious adverse events
Measure: Incidence of adverse event Time: Day 0 to day 28 or patients discharge dayAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports